Related Experiment Video
Updated: Feb 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Update on Biosimilars in Asia
1School of Medicine Kaohsiung Medical University, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung, Taiwan. d10153@ms14.hinet.net.
Purpose Of Review:
This review provides an update on the evolution of, manufacturing of, and regulations for biosimilars in Asian countries.
Recent Findings:
The use of biologics revolutionized the treatment of various diseases. However, the high cost of biologics remained unaffordable for most Asian patients and increases the financial burden of Asian governments. The development of biosimilars provides the best solution for this predicament. A great boom of biosimilars is developing in Asia. Hundreds of biopharmaceutical companies have established their manufacturing facilities and provide affordable products for Asian patients. Regulation guidelines and international harmonization are evolving. Better manufacturing quality and post-market pharmacovigilance are needed in Asia despite the rapid evolution of biosimilar development.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Pharmaceutical Equivalents
Bioequivalence studies: Biowaivers
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

